Samples of drugs used in diabetes, hypertension, allergies, infections found substandard in quality tests

Jaipur: Samples of five drugs were found to be of substandard quality upon testing and analysis conducted by the Commissionerate, Food Safety and Drug Control (CFSDC).

On Wednesday, the CFSDC issued directions to all the district drug controllers in the state to ensure that the stocks of these drugs are no longer consumed. They were instructed to provide appropriate safeguards to consumers by withdrawing the available stock and taking action as per the provisions of the Drugs & Cosmetics Act 1940.

A senior CFSDC official said, samples of Levocetirizine Dihydrochloride Tablets (Wincet-L), manufactured by M/s YL Pharma of Baddi in Solan district, Himachal Pradesh, were found to be of substandard quality. The drug was sold as an antihistamine used to treat symptoms associated with various allergic conditions.

A sample of Voglibose tablets 0.3 mg (DULCOVOG-0.3), manufactured by M/s Lifecare Neuro Products Ltd of Dharampur in Himachal Pradesh, failed the quality test. The drug is used as an antidiabetic medication to manage type 2 diabetes mellitus.
A sample of Ofloxacin Tablets IP 200 mg (OFWIN-200), manufactured by M/s YL Pharma of Baddi in Solan, failed the quality test. The drug is a fluoroquinolone antibiotic used to treat a variety of bacterial infections.

A sample of Telmisartan and Amlodipine Tablets IP (Telpin-A), manufactured by India M/s Maskon Life Sciences Pvt. Ltd in Bhagwanpur of Roorkee, was found to be of substandard quality. The drug is used as a combination medication to treat high blood pressure (hypertension) in adults.

The CFSDC tested a sample of Cefixime Oral Suspension manufactured by M/s Agron Remedies Pvt. Ltd of Sarverkhera, Uttarakhand, which failed the quality test. It is used as an antibiotic medication to treat a variety of bacterial infections, particularly in children and adults who have difficulty swallowing pills.

Related Posts

Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US

Taro Pharmaceutical, a subsidiary of Sun Pharmaceutical, has initiated a recall of over 17,000 units of an antifungal shampoo in the United States after manufacturing issues were flagged by the…

Strides Pharma Science arm New York facility gets 4 USFDA observations

Bengaluru: Strides Pharma Science has announced that the U.S. Food and Drug Administration (USFDA) has concluded inspection with four observations at the Formulations Facility of Strides Pharma Inc. USA (SPI),…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US

Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US

Strides Pharma Science arm New York facility gets 4 USFDA observations

Strides Pharma Science arm New York facility gets 4 USFDA observations

SSI Mantra, Made in India Robot, bats a Thousand by completing 100 Telesurgeries

SSI Mantra, Made in India Robot, bats a Thousand by completing 100 Telesurgeries

Bihar drug bust: Rs15 million narcotics seized in major trafficking crackdown

Bihar drug bust: Rs15 million narcotics seized in major trafficking crackdown

Top pharma companies racing to launch first weight-loss pill

Top pharma companies racing to launch first weight-loss pill

Ajanta Pharma shares rise 5% on Biocon weight-loss drug marketing pact

Ajanta Pharma shares rise 5% on Biocon weight-loss drug marketing pact